Savara (SVRA) Tax Provisions (2017 - 2018)
Savara (SVRA) reported Tax Provisions of $2.5 million for Q4 2018, up 24900.0% year-over-year from N/an in Q4 2017, and up 2372.73% on a QoQ basis from -$110000.0 in Q3 2018.
Savara (SVRA) has 2 years of Tax Provisions data on file, last reported at $2.5 million in Q4 2018.
- Quarterly Tax Provisions rose 24900.0% year-over-year to $2.5 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was -$2.4 million (down 200.0% YoY) and the FY2018 annual result came in at -$7.1 million, down 766.95% from the prior year.
- Tax Provisions improved to $2.5 million in Q4 2018 per SVRA's latest filing, from -$110000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $2.5 million in Q4 2018 and bottomed at -$4.6 million in Q1 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 2.50 Mn |
| Sep 30, 2018 | -110,000.00 |
| Jun 30, 2018 | -277,000.00 |
| Mar 31, 2018 | -4.56 Mn |
| Dec 31, 2017 | 10,000.00 |
| Sep 30, 2017 | -117,000.00 |
| Jun 30, 2017 | -470,000.00 |
| Mar 31, 2017 | -237,000.00 |